Enhancing the Efficacy of Immunotherapeutic Drugs for Prostate Cancer – Dr Douglas McNeel, MD PhD, University of Wisconsin

Apr 25, 2019 | biology, health and medicine

Original Article Reference

https://doi.org/10.33548/SCIENTIA346

About this episode

Prostate cancer is a leading cause of male cancer deaths worldwide, with one man in every seven likely to contract the disease during his lifetime. As late-stage prostate cancer remains a fatal disease resistant to conventional treatment, the need for effective new therapies is dire. Dr Douglas McNeel, a Professor of Medicine in the Haemato-Oncology Division of the University of Wisconsin’s Carbone Cancer Centre, has been working to meet this need.
 

 

This work is licensed under a Creative Commons Attribution 4.0 International LicenseCreative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium

or format

Adapt: You can change, and build upon the material for any

purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the

license, and indicate if changes were made.

Related episodes

Dr. Sarallah Rezazadeh | Unlocking the Secrets of Aging: How Stem Cells Hold the Key to Vitality

Dr. Sarallah Rezazadeh | Unlocking the Secrets of Aging: How Stem Cells Hold the Key to Vitality

Aging is a tale written by the cells in our bodies, although some cell types play a bigger role than others. At the crux of this story is an intriguing protagonist: the stem cell. These master builders, which can differentiate into any cell type, thereby helping to replace diseased or worn-out tissues, are essential for tissue repair and in maintaining health into old age. But as we get older, the capabilities of stem cells gradually diminish, which is known as stem cell exhaustion and is a key facet of aging itself. Stem cell exhaustion plays a role in a large number of age-related diseases, meaning that it could be a crucial research target in developing new treatments and techniques to help us age well. A Research Topic in the open-access journal Frontiers in Aging has been curated by Dr. Sarallah Rezazadeh of the Icahn School of Medicine at Mount Sinai and Professor Georgina May Ellison-Hughes of King’s College London. The Topic collects groundbreaking studies into stem cell exhaustion under one open-access roof, exploring the detailed mechanisms underlying the phenomenon and establishing the field in a wider context to identify promising therapeutic approaches for those later in life.

Dr. Mingjun Xie | A Blueprint for Life: Creating Blood Vessels in Bioprinted Tissues

Dr. Mingjun Xie | A Blueprint for Life: Creating Blood Vessels in Bioprinted Tissues

A future where injured or diseased organs can be removed and replaced with new lab-printed tissues that are customized specifically for each patient is not as far away as you might think. These functional and living tissues could grow naturally within the body, and repair and sustain themselves over time. While these concepts were once in the realm of science fiction, advances in bioprinting, which is a form of 3D printing using biological “inks” (known as bioinks) loaded with living cells, are bringing them closer to reality. Among the researchers advancing this field is Dr. Mingjun Xie of Zhejiang University, China, and colleagues, who are performing work that addresses a significant challenge in bioprinting. This involves creating large portions of tissues that have a functional vasculature, thereby mimicking the complexity of native tissues and organs.

Prof. Eugenio Cersosimo | Cardio-Renal Protection and Blood Sugar Balance: How SGLT-2 Inhibitors Are Changing Diabetes Care

Prof. Eugenio Cersosimo | Cardio-Renal Protection and Blood Sugar Balance: How SGLT-2 Inhibitors Are Changing Diabetes Care

In their ongoing quest to improve diabetes management, researchers are searching for new insights into the mechanisms through which the body manages blood sugar levels. Prof. Eugenio Cersosimo and colleagues at the University of Texas Health Science Center recently reported a breakthrough that could change how we understand glucose control and increase our ability to manage type 2 diabetes. Their study examines two medications, dapagliflozin, an SGLT-2 inhibitor, and exenatide, a GLP-1 receptor agonist, and how they can work together to control blood sugar levels by exploiting a previously unknown kidney-to-liver signalling pathway. Their findings have unravelled some important underlying mechanisms that provide strong support for the cardio-renal protective effects reported in many large clinical trials with the use of SGLT-2 inhibitors in patients with type 2 diabetes. The demonstration that the kidney plays a central role in glucose regulation during exposure to SGLT-2 inhibitors represents a major advance in our understanding of diabetes treatment and the prevention of severe cardiovascular and renal complications.

Charles Frison-Roche | The Hidden Architects of Movement: The Role of MBNL Proteins in Movement

Charles Frison-Roche | The Hidden Architects of Movement: The Role of MBNL Proteins in Movement

Researchers have made a significant advancement in understanding an important component of the nervous system: the neuromuscular junction, a crucial connection between nerves and muscles. A recent study performed by Charles Frison-Roche of the Center of Research in Myology in the Sorbonne University, Paris, and colleagues, reveals the role of proteins known as Muscleblind-like proteins, or MBNL proteins for short, which help to regulate motor coordination by helping to maintain neuromuscular junction stability. This discovery is potentially very useful, as loss-of-function of MBNL proteins is a hallmark of a genetic condition called Myotonic Dystrophy type 1 (or DM1 for short). DM1 disrupts muscle control, leading to muscle weakness, problems with balance, and other symptoms that can get progressively worse over time. MBNL proteins, and their role in the neuromuscular junction, may represent new treatment targets in DM1.

Increase the impact of your research

• Good science communication helps people make informed decisions and motivates them to take appropriate and affirmative action.

• Good science communication encourages everyday people to be scientifically literate so that they can analyse the integrity and legitimacy of information.

• Good science communication encourages people into STEM-related fields of study and employment.

• Good public science communication fosters a community around research that includes both members of the public, policymakers and scientists.

• In a recent survey, 75% of people suggested they would prefer to listen to an interesting story than read it.

Step 1

Upload your science paper

Step 2

SciPod script written

Step 3

Voice audio recorded

Step 4

SciPod published